WuXi XDC Cayman Inc
Company Profile
Business description
WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.
Contact
No. 11 Xinhui Ring Road
Xinwu
Jiangsu Province
Wuxi
CHNSector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
2,270
Stocks News & Analysis
stocks
Chart of the Week: Soft earnings growth outlook for Australian banks
stocks
Coca-Cola earnings: Billion-dollar brands and consumer engagement remain growth priorities
stocks
Unwarranted drop in ASX share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,281.80 | 97.30 | 1.06% |
| CAC 40 | 8,313.24 | 14.64 | -0.18% |
| DAX 40 | 24,856.15 | 131.70 | -0.53% |
| Dow JONES (US) | 50,078.06 | 110.08 | -0.22% |
| FTSE 100 | 10,472.11 | 118.27 | 1.14% |
| HKSE | 27,266.38 | 83.23 | 0.31% |
| NASDAQ | 23,088.41 | 14.06 | -0.06% |
| Nikkei 225 | 57,650.54 | 1,286.60 | 2.28% |
| NZX 50 Index | 13,507.28 | 60.91 | 0.45% |
| S&P 500 | 6,946.14 | 4.33 | 0.06% |
| S&P/ASX 200 | 9,014.80 | 98.80 | 1.11% |
| SSE Composite Index | 4,131.98 | 3.61 | 0.09% |